Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 22%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia is poised for success with its unique PRINT technology and promising products targeting rare cardiopulmonary diseases like PH and PH-ILD. With YUTREPIA, L606, and RareGen all showing potential for strong market penetration, combined with a robust pipeline, Liquidia is well-positioned for long-term growth in a largely underpenetrated market. While there is legal risk looming with ongoing litigation regarding UTHR's patents, Liquidia's strong financials and promising data make it a sound investment for those looking for exposure in the biopharmaceutical sector.

Bears say

Liquidia is facing significant legal risks, including ongoing lawsuits that could disrupt sales of their lead product Yutrepia and potentially limit future growth. Additionally, while the company's inhaled treprostinil product may have a larger market and less competition than its other product for treatment of pulmonary arterial hypertension, there is still potential for regulatory and pricing challenges. These risks, coupled with the company's current negative cash flow and increasing competition, contribute to a negative outlook on Liquidia's stock.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.